

---

primary studies - published RCT

# The Effect of Control IQ Hybrid Closed Loop Technology on Glycemic Control in Adolescents and Adults with Cystic Fibrosis-Related Diabetes.

**Code:** PM35020476

**Year:** 2022 **Date:** 1987

**Author:** Scully KJ

## Study design (if review, criteria of inclusion for studies)

prospective double-blind placebo-controlled study

## Participants

40 patients with cystic fibrosis and chronic broncho-pulmonary *Pseudomonas aeruginosa* infection

## Interventions

Active treatment consisted of inhalation of colistin one million units twice daily for three months and was compared to placebo inhalations of isotonic saline.

## Outcome measures

clinical symptom score, maintenance of pulmonary function and inflammatory parameters.

## Main results

Significantly more patients in the colistin inhalation group completed the study as compared to the placebo group (18 versus 11). Colistin treatment was superior to placebo treatment in terms of a significantly better clinical symptom score, maintenance of pulmonary function and inflammatory parameters.

## Authors' conclusions

Colistin inhalation therapy for cystic fibrosis patients with chronic *P. aeruginosa* lung infection can be a supplementary treatment to frequent courses of intravenous anti-pseudomonas chemotherapy.

<http://dx.doi.org/10.1089/dia.2021.0354>

## See also

Diabetes Technol Ther. 2022 Jun;24(6):446-452. doi: 10.1089/dia.2021.0354. Epub 2022 May 12.

## Keywords

Adolescent; Adult; Anti-Bacterial Agents; Bacterial Infections; Child; Colistin; Infection; Inhalation OR nebulised; pharmacological\_intervention; *Pseudomonas aeruginosa*; *Pseudomonas*; Respiratory Tract Diseases; Respiratory Tract Infections; other anti-bacterial agents;